Lv52
856 积分 2023-06-27 加入
Oral Selective Estrogen Receptor Degrader for Advanced Breast Cancer
4小时前
求助中
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
5天前
已关闭
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
12天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
12天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
23天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
28天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
29天前
已完结
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
29天前
已完结
In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry
29天前
已完结
In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry
29天前
已完结
皖公网安备34019202002308
